Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Joshua G, Nichols"'
Autor:
Lingdi Zhang, Xue-hai Liang, Cheryl Li De Hoyos, Michael Migawa, Joshua G. Nichols, Graeme Freestone, Jun Tian, Punit P. Seth, Stanley T. Crooke
Publikováno v:
Nucleic Acid Therapeutics. 32:401-411
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d010ee80d944483c78c624b02605c89a
https://doi.org/10.1089/nat.2022.0005
https://doi.org/10.1089/nat.2022.0005
Publikováno v:
Nucleic Acid Therapeutics. 31:284-297
Phosphorothioate-modified antisense oligonucleotide (PS-ASO) drugs are commonly used to modulate gene expression through RNase H1-mediated cleavage of target RNAs. Upon internalization through endocytic pathways into cells, PS-ASOs must be released f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3c03d4df575aded5b29f30b16f0d035
https://doi.org/10.1089/nat.2020.0920
https://doi.org/10.1089/nat.2020.0920
Autor:
Hong Sun, Joshua G Nichols, Stanley T. Crooke, Lingdi Zhang, Cheryl L De Hoyos, Xue-hai Liang
Publikováno v:
Nucleic Acids Research
Phosphorothioate (PS) modified antisense oligonucleotide (ASO) drugs can trigger RNase H1 cleavage of cellular target RNAs to modulate gene expression. Internalized PS-ASOs must be released from membraned endosomal organelles, a rate limiting step th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4e55b6f52ede0b9199abce7db93f77e
https://doi.org/10.1093/nar/gkab599
https://doi.org/10.1093/nar/gkab599
Autor:
Lingdi, Zhang, Xue-Hai, Liang, Cheryl Li, De Hoyos, Michael, Migawa, Joshua G, Nichols, Graeme, Freestone, Jun, Tian, Punit P, Seth, Stanley T, Crooke
Publikováno v:
Nucleic acid therapeutics. 32(5)
Antisense oligonucleotides (ASOs) that mediate RNA target degradation by RNase H1 are used as drugs to treat various diseases. Previously we found that introduction of a single 2'
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::72a1e86ce112d315f4bbadf9d26eeb8d
https://pubmed.ncbi.nlm.nih.gov/35861704
https://pubmed.ncbi.nlm.nih.gov/35861704
Publikováno v:
Nucleic Acids Research
Antisense oligonucleotide (ASO) drugs that trigger RNase H1 cleavage of target RNAs have been developed to treat various diseases. Basic pharmacological principles suggest that the development of tolerance is a common response to pharmacological inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cf013b32d3b2becd3fb179427755455
http://europepmc.org/articles/PMC7515700
http://europepmc.org/articles/PMC7515700
Publikováno v:
Nucleic Acids Research
Phosphorothioate (PS) modified antisense oligonucleotide (ASO) drugs that act on cellular RNAs must enter cells and be released from endocytic organelles to elicit antisense activity. It has been shown that PS-ASOs are mainly released by late endosom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0125210e4d9a074fd57b742917035316
https://pubmed.ncbi.nlm.nih.gov/34878127
https://pubmed.ncbi.nlm.nih.gov/34878127
Autor:
Hong Sun, Stanley T. Crooke, Timothy A. Vickers, Cheryl L De Hoyos, Chih-Wei Hsu, Joshua G Nichols, Xue-hai Liang
Publikováno v:
Nucleic Acids Research
Release of phosphorothioate antisense oligonucleotides (PS-ASOs) from late endosomes (LEs) is a rate-limiting step and a poorly defined process for productive intracellular ASO drug delivery. Here, we examined the role of Golgi-endosome transport, sp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a156e8c5af7c48930d8bba22c5e38b9b
https://doi.org/10.1093/nar/gkz1171
https://doi.org/10.1093/nar/gkz1171
Autor:
Xue-hai Liang, Shiyu Wang, Chih-Wei Hsu, Stanley T. Crooke, Wen Shen, Timothy A. Vickers, Nickolas Allen, Joshua G Nichols, Hong Sun
Publikováno v:
Nucleic Acids Research
RNase H1-dependent, phosphorothioate-modified antisense oligonucleotides (PS-ASOs) can enter cells through endocytic pathways and need to be released from the membrane-enclosed organelles, a limiting step for antisense activity. Accumulating evidence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::704dc7f1d8b16d6b40c6fe6d2139b50a
https://doi.org/10.1093/nar/gky841
https://doi.org/10.1093/nar/gky841
Publikováno v:
Molecular Therapy
RNase H1-dependent antisense oligonucleotides (ASOs) are active in reducing levels of both cytoplasmic mRNAs and nuclear retained RNAs. Although ASO activity in the nucleus has been well demonstrated, the cytoplasmic activity of ASOs is less clear. U
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f70dc1f93c0200e80015dc76d176378
https://doi.org/10.1016/j.ymthe.2017.06.002
https://doi.org/10.1016/j.ymthe.2017.06.002
Autor:
Wen Shen, Joshua G Nichols, Thazha P. Prakash, Hong Sun, Garth A. Kinberger, Xue-hai Liang, Stanley T. Crooke
Publikováno v:
Nucleic Acids Research
RNase H1-dependent antisense oligonucleotides (ASOs) are chemically modified to enhance pharmacological properties. Major modifications include phosphorothioate (PS) backbone and different 2'-modifications in 2-5 nucleotides at each end (wing) of an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce461751f1df6fe8316d85db56436774
https://doi.org/10.1093/nar/gkw144
https://doi.org/10.1093/nar/gkw144